Recommendations from the national multiple sclerosis society clinical outcomes assessment task force

被引:283
作者
Rudick, R
Antel, J
Confavreux, C
Cutter, G
Ellison, G
Fischer, J
Lublin, F
Miller, A
Petkau, J
Rao, S
Reingold, S
Syndulko, K
Thompson, A
Wallenberg, J
Weinshenker, B
Willoughby, E
机构
[1] MCGILL UNIV,MONTREAL NEUROL INST,MONTREAL,PQ,CANADA
[2] HOP DE ANTIQUAILLE,LYON,FRANCE
[3] AMC,CTR CANC RES,DENVER,CO
[4] UNIV CALIF LOS ANGELES,MED CTR,LOS ANGELES,CA 90024
[5] MAIMONIDES HOSP,BROOKLYN,NY 11219
[6] UNIV BRITISH COLUMBIA,VANCOUVER,BC V5Z 1M9,CANADA
[7] MED COLL WISCONSIN,MILWAUKEE,WI 53226
[8] NATL MULTIPLE SCLEROSIS SOC,NEW YORK,NY
[9] W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073
[10] INST NEUROL,LONDON WC1N 3BG,ENGLAND
[11] BERLEX LABS INC,RICHMOND,CA
[12] MAYO CLIN,ROCHESTER,MN
[13] AUCKLAND HOSP,AUCKLAND,NEW ZEALAND
关键词
D O I
10.1002/ana.410420318
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This article provides recommendations from the National Multiple Sclerosis Society's Clinical Outcomes Assessment Task Force. The Task Force was appointed in 1994 and charged with recommendending improved approaches for clinical outcomes assessment in future controlled clinical trials. The recommendations herein follow extensive deliberation and data analysis during 2.5 years. General principles and desirable measurement attributes were used to assess alternative measurement techniques and clinical scales. On the basis of the analysis of existing multiple sclerosis (MS) data sets, a new measurement approach is proposed. The approach is based on quantitative functional composites that consist of simple quantitative measures from the major clinical dimensions of MS combined into a single score. Quantitative functional composites are likely to provide improved precision and sensitivity in future MS clinical trials. Studies necessary to further refine quantitative functional composites as useful MS clinical trial outcomes are delineated.
引用
收藏
页码:379 / 382
页数:4
相关论文
共 15 条
  • [1] Benton AL., 1976, MULTILINGUAL APHASIA
  • [2] A PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-MASKED, VARIABLE DOSAGE, CLINICAL-TRIAL OF AZATHIOPRINE WITH AND WITHOUT METHYLPREDNISOLONE IN MULTIPLE-SCLEROSIS
    ELLISON, GW
    MYERS, LW
    MICKEY, MR
    GRAVES, MC
    TOURTELLOTTE, WW
    SYNDULKO, K
    HOLEVOETHOWSON, MI
    LERNER, CD
    FRANE, MV
    PETTLERJENNINGS, P
    [J]. NEUROLOGY, 1989, 39 (08) : 1018 - 1026
  • [3] GOLDSMITH CH, 1993, J RHEUMATOL, V20, P575
  • [4] LOW-DOSE (7.5-MG) ORAL METHOTREXATE REDUCES THE RATE OF PROGRESSION IN CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS
    GOODKIN, DE
    RUDICK, RA
    MEDENDORP, SV
    DAUGHTRY, MM
    SCHWETZ, KM
    FISCHER, J
    VANDYKE, C
    [J]. ANNALS OF NEUROLOGY, 1995, 37 (01) : 30 - 40
  • [5] GOODKIN DE, 1988, ARCH PHYS MED REHAB, V69, P850
  • [6] PACED AUDITORY SERIAL-ADDITION TASK - MEASURE OF RECOVERY FROM CONCUSSION
    GRONWALL, DMA
    [J]. PERCEPTUAL AND MOTOR SKILLS, 1977, 44 (02) : 367 - 373
  • [7] INTENSIVE IMMUNOSUPPRESSION IN PROGRESSIVE MULTIPLE-SCLEROSIS - A RANDOMIZED, 3-ARM STUDY OF HIGH-DOSE INTRAVENOUS CYCLOPHOSPHAMIDE, PLASMA-EXCHANGE, AND ACTH
    HAUSER, SL
    DAWSON, DM
    LEHRICH, JR
    BEAL, MF
    KEVY, SV
    PROPPER, RD
    MILLS, JA
    WEINER, HL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (04) : 173 - 180
  • [8] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis
    Jacobs, LD
    Cookfair, DL
    Rudick, RA
    Herndon, RM
    Richert, JR
    Salazar, AM
    Fischer, JS
    Goodkin, DE
    Granger, CV
    Simon, JH
    Alam, JJ
    Bartoszak, DM
    Bourdette, DN
    Braiman, J
    Brownscheidle, CM
    Coats, ME
    Cohan, SL
    Dougherty, DS
    Kinkel, RP
    Mass, MK
    Munschauer, FE
    Priore, RL
    Pullicino, PM
    Scherokman, BJ
    WeinstockGuttman, B
    Whitman, RH
    Baird, WC
    Fillmore, M
    Bona, LM
    ColonRuiz, ME
    Nadine, BS
    Donovan, A
    Bennett, S
    Kieffer, YM
    Umhauer, MA
    Miller, CE
    Kilic, AK
    Sargent, EL
    Schachter, M
    Shucard, DW
    Weider, V
    Catalano, BA
    Cervi, JM
    Czekay, C
    Farrell, JL
    Filippini, JS
    Matyas, RC
    Michienzi, KE
    Ito, M
    OMalley, JA
    [J]. ANNALS OF NEUROLOGY, 1996, 39 (03) : 285 - 294
  • [9] KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
  • [10] *MULT SCLER STUD G, 1990, ANN NEUROL, V27, P591